Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Submental Fat
Interventions: LIPO-202, Placebo for LIPO-202; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more

Conditions: Healthy Volunteer
Interventions: TAK-951, TAK-951 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Myelodysplastic Syndromes
Interventions: Oral rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 10
States / cities: Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Orthopaedic Trauma, Chronic Opioid Use
Interventions: Ketorolac Injection, Standard of Care (SOC) Multimodal Analgesia; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Warm Antibody Autoimmune Hemolytic Anemia
Interventions: Fostamatinib disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 26
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: Respiratory Distress Syndrome in Premature Infant
Interventions: AeroFact, nCPAP; Drug · Other
Lead sponsor: Aerogen Pharma Limited; Industry
Eligibility: 26 Weeks to 31 Weeks
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 37
States / cities: Little Rock, Arkansas • Berkeley, California • Orange, California + 27 more

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Brain Tumor, Recurrent
Interventions: Photofrin photodynamic therapy.; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypogonadism, Opioid-Related Disorders, Male Infertility
Interventions: Clomiphene citrate, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: atazanavir, danoprevir, ritonavir, tenofovir disoproxil fumarate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy, Dense Breasts
Interventions: Molecular Breast Imaging, MBI-guided biopsy; Device
Lead sponsor: Smart Breast Corp.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 3
States / cities: Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: Relapsed/Refractory Ovarian Carcinoma
Interventions: NTB-928; Drug
Lead sponsor: TeneoSeven, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Birmingham, Alabama • Omaha, Nebraska • Lake Success, New York + 1 more

Conditions: Parenteral Nutrition-Associated Liver Disease
Interventions: Intravenous fat emulsion, Restriction of intravenous fat emulsion to 1 gm/kg/d; Other
Lead sponsor: Yale University; Other
Eligibility: 12 Hours to 48 Hours
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer, Cardiovascular Disease
Interventions: Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor; Behavioral · Drug
Lead sponsor: McMaster University; Other
Eligibility: 45 Years and older · Male only
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 4
States / cities: Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more

Conditions: Genitourinary Syndrome of Menopause
Interventions: StrataMGT, Estrace 0.01% Vaginal Cream; Device · Drug
Lead sponsor: Stratpharma AG; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Laguna Hills, California • Miami, Florida • Johns Creek, Georgia

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
Interventions: AIV007; Drug
Lead sponsor: AiViva BioPharma, Inc.; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more

Conditions: Lysosomal Diseases, Gangliosidosis, GM1
Interventions: AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam; Biological · Procedure · Drug + 3 more
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Severe to Critical COVID 19 With Associated ARDS
Interventions: FP-025 100 mg, FP-025 300 mg, Placebo; Drug
Lead sponsor: Foresee Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Chula Vista, California • La Mesa, California • Rockville, Maryland + 4 more

Conditions: Type 2 Diabetes Mellitus, Bone Remodeling
Interventions: exenatide, Saline; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 45 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Crohn's Disease
Interventions: Naltrexone, Placebo, sugar pill; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Interventions: LHP588, Placebo Drug; Drug
Lead sponsor: Lighthouse Pharmaceuticals, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Murrieta, California + 34 more

Conditions: Tennis Elbow
Interventions: TenoMiR, 0.9% Sodium Chloride Injection; Drug
Lead sponsor: Causeway Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Redwood City, California • New York, New York

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

A Study of TAK-951 in Healthy Adults

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

ACTIV-2: A Study for Outpatients With COVID-19

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Molecular Breast Imaging (MBI)-Guided Biopsy

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Study of NTB-928 in R/R OC

Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

Effect of AIV007 by Periocular Administration in Subjects With Macular Edema Secondary to nAMD and DME

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Efficacy and Safety of TenoMiR in Lateral Epicondylitis